STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Amylyx Pharmaceuticals: Results from the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia, a rare metabolic condition that causes severe drops in blood sugar. 

Biogen: In May, the company announced results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease called diranersen that targets the protein tau. Detailed data from the study will be presented on July 14 at the Alzheimer’s Association International Conference. 

Continue to STAT+ to read the full story…